Blood Pressure Tablet Recall UK: What Patients Need to Know

Brits who use a common blood pressure medication have been urged to watch out for a 7-digit code after a nationwide recall was issued by health regulators. The medication was recently recalled following a packaging mix-up, leaving pharmacists to quarantine stock across the country. One batch of Lercanidipine Hydrochloride 10mg tablets has been recalled by Accord-UK Ltd. due to a packaging error involving tablets of the incorrect strength.

The common medication is used by hundreds of thousands of Brits every year to help manage high blood pressure, medically known as hypertension, by relaxing and widening the blood vessels. Managing this condition is vital for preventing strokes, heart attacks, and kidney disease. When packaging errors occur, patients face potential risks regarding their prescribed dosage levels, prompting immediate regulatory intervention.

Understanding the Lercanidipine Hydrochloride Recall

In a complaint received by the Medicines and Healthcare products Regulatory Agency, a box was found to contain one strip of the 10mg dose and one strip of the 20mg dose. This discrepancy means patients could inadvertently ingest double their prescribed active ingredient strength without realizing the change. Regulatory bodies monitor pharmaceutical manufacturing closely to catch these errors before widespread harm occurs.

If a patient prescribed a 10mg dosage took 20mg for two weeks, they could experience exaggerated pharmacological risks caused by reduced blood pressure, such as dizziness and palpitations. Other symptoms of excessively low blood pressure can include fainting, fatigue, and blurred vision. Because high blood pressure treatments alter cardiovascular dynamics, precise dosing is critical for safe daily management.

How to Check Your Blood Pressure Medication Box

Those who have a prescription for Lercanidipine Hydrochloride 10mg can find out if they have the affected batch by looking for the code printed on the packaging. On the side of the box, the affected batch will display the number M2510877 as well as the expiry date of 11/2028. Patients should inspect their medication storage areas immediately if they currently hold this specific drug.

Another way of spotting the difference between dosages is the colour and physical dimensions of the pills themselves. The 10mg dose is yellow and smaller, while the 20mg version is pink and bigger. Visual checks serve as a secondary line of defense for patients handling potent pharmaceutical products at home.

Instructions for Checking Blister Strips and Cartons

If the affected cartons contain blister strips that are clearly labelled Lercanidipine Hydrochloride 10mg, no further action is required by the patient. However, if they are labelled 20mg, do not take the medicine, contact your pharmacy, and seek immediate medical advice if experiencing side effects. Clear labelling on internal blister packs helps individuals identify discrepancies even after discarding the outer cardboard box.

Any suspected adverse reactions can also be reported through the MHRA Yellow Card scheme, which allows patients and medical professionals to log drug side effects. This reporting system helps public health authorities track safety issues and monitor medication performance across the population.

Pharmacist Actions and Supply Chain Response

This recall is currently being conducted on a pharmacy and wholesale level, and the overall risk to patients is considered to be low by health authorities. Supply chain safeguards ensure that distribution networks are alerted quickly when manufacturing errors are identified. Pharmacists who stock the drug have been urged to stop supplying the above batch immediately and quarantine all remaining stock so it can be returned to the supplier.

Wholesalers and retail pharmacies must follow strict protocols to isolate recalled goods from active inventory. This quarantine process prevents any further dispensing of the affected batch while investigations continue between the manufacturer and the regulatory agency.